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Abstract
Background: Demonstration of equivalent amounts of the same active pharmaceutical ingredient
(API) between generic and innovator products (pharmaceutical equivalence) is a basic requirement
of regulatory agencies for intravenous generic drugs prior to clinical use, and constitutes the pivotal
point to assume therapeutic equivalence. Physicochemical methods are preferred instead of
biological assays to determine concentration of drugs in biological fluids, but it does not permit
direct quantification of potency. Here, we report a microbiological assay using large plates designed
to determine potency and concentration of pharmaceutical-grade antibiotics for injection and a
statistical method to assess the in vitro equivalence of generic products with respect to the
innovator.
Methods: The assay is based on the concentration-dependent variation of the inhibitory effect of
antibiotics on reference bacteria (B. subtilis ATCC 6633, S. aureus ATCC 6538p and S. epidermidis
ATCC 12228) in a seeded agar (Difco™ Antibiotic Media), producing a concentration-response
linear relationship with two parameters: y-intercept (concentration) and slope (potency). We
compared the parameters of 22 generic products (amikacin 4, gentamicin 15, and vancomycin 3
products) against the innovator and the reference powder by Overall Test for Coincidence of the
Regression Lines (Graphpad Prism 5.0).
Results: The validation method yielded excellent results for linearity (r2 ≥ 0.98), precision (intra-
assay variation ≤ 11%; inter-assay variation ≤ 10%), accuracy, and specificity tests according to
international pharmacopoeial requirements. Except for one generic of vancomycin that had 25%
more API (Py-intercept = 0.001), the pharmaceutical equivalence was demonstrated in 21 generics with
undistinguishable slopes and intercepts (P > 0.66). Potency estimates were 99.8 to 100.5, 99.7 to
100.2 and 98.5 to 99.9% for generic products of amikacin, gentamicin and vancomycin, respectively.
Conclusion: The proposed method allows rapid, cost-saving, precise, and accurate determination
of pharmaceutical equivalence of drugs in pharmaceutical dosage-form, and may be used as a
technique for testing generic antibiotics prior to their approval for human use.
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Background
Although resistance is a real and growing problem, the
antimicrobials remain one of the three most prescribed
drugs. Currently, the global anti-infective market is valued
at US$66.5 billion with antibacterial agents accounting
for over 50% of sales [1]. This remarkable cost has
resulted in a massive use of generic drugs trying to assure
unlimited access to cheap treatments, to the point that
currently over half prescriptions include at least one
generic product [2,3]. However, the phenomenal growth
of generic drugs has brought concerns about their safety
and efficacy because, opposite to innovators, generics are
not required to demonstrate therapeutic efficacy [4-11]. In
fact, pharmaceutical equivalence, defined as having
equivalent amounts of the same active pharmaceutical
ingredient (API) of the innovator, in the same dosage
form, and produced under good manufacturing practices,
constitutes the only criterion required for therapeutic
equivalence of intravenous drugs [12]. Therefore, the
quantification of API in standard samples or biological
fluids is critical for drug regulatory agencies around the
world.
Several analytical methods have been reported to quantify
the concentration of API. They can be classified as micro-
biological assays (bioassay) [13,14], automated physico-
chemical assays (i.e. high performance liquid
chromatography, HPLC) [15], and immunological assays
(i.e. fluorescence polarization immunoassay) [16-18].
Automated chemical methods have largely replaced the
microbiological assays to determine the antibiotic con-
centrations in body fluids (e.g. serum, plasma or urine),
especially for therapeutic drug monitoring (TDM) in clin-
ical settings, because they are more attractive than the clas-
sical bioassay in terms of speed, accuracy and precision
[13,15,19]. However, automated assays and bioassays are
frequently used and accepted by generic manufacturers as
interchangeable and complementary to the other meth-
ods [20,21]. The main disadvantage of microbiological
assays is the inability to quantify substances other than
the API in the same matrix (i.e. metabolites or impurities).
Although pharmaceutical-grade drugs usually are a mix of
API plus preservatives, vehicles and impurities with differ-
ent sources between manufacturers, regulatory agencies
do not require the determination of these substances to
define a generic as pharmaceutical equivalent, reducing
the importance of this disadvantage [22].
The microbiological assay for antibiotics dates back to the
demonstration of the lysozyme activity in an agar diffu-
sion assay by Fleming, shortly followed by the agar diffu-
sion assay for penicillin devised by Heatley [19]. Ever
since, the main uses of agar diffusion assay were determi-
nation of potency of growth-inhibiting (i.e. antibiotics)
and growth-promoting substances (i.e. amino acids) in
blood, urine, and other body fluids and tissues, mainly for
pharmacokinetic studies. An additional use of bioassay
was recognized after the Drug Price Competition and Pat-
ent Term Restoration Act of 1984, when the measurement
of antibiotic concentrations in various fluids was promi-
nent to establish pharmaceutical equivalence of new
generics and as manufacture quality control [13,23]. For
this purpose, the calculation is based on the assumption
of two symmetrical (each preparation has the same
number of dose levels in the same ratio to one another)
straight parallel-lines (so called "parallel-line assay"), one
being a plot of the response (mean zone size) against the
logarithmic concentration of the standard, the other being
a plot of responses against the log concentration of the
unknown product. The relative potency of unknown to
standard reference is derived from the horizontal distance
between the two lines. Usually, the recommended stand-
ard is a pure-grade product of known potency. However,
no statistical procedure has been standardized to compare
simultaneously the potency of two pharmaceutical-grade
products (generic versus innovator) and the currently
used method does not allow separation of concentration
from potency. Additionally, complex pharmacopoeial
guidelines on bioassay design and validation are availa-
ble, including requirements for validity of parallel-line
assays concerning precision, accuracy, sensitivity, and var-
iance ratios for linear regression, non-parallelism and
non-linearity. Here we propose a new and more under-
standable interpretation of the parallel-line assay results
to determine pharmaceutical equivalence, comparing the
dose-response relationship obtained with the pharmaceu-
tical form of innovator versus generic by curve fitting anal-
ysis and performing an intra-house validation of the
procedure assessing the same criteria recommended by
international pharmacopoeias.
Methods
Antibiotics
Intravenous antibiotics for human use were bought from
reputable local drugstores as needed. All products had
been properly licensed by the drug regulatory agency of
Colombia. We used the innovators of amikacin (Amikin®,
Bristol-Myers Squibb, Guayaquil, Ecuador), gentamicin
(Garamicina®, Schering-Plough SA, Bogota, Colombia)
and vancomycin (Vancocin CP®, Eli Lilly & Compañia de
Mexico SA de CV, Mexico), as well as the available generic
products: four of amikacin, fifteen of gentamicin and
three of vancomycin (N = 22 generic products). All prod-
ucts were reconstituted with calibrated micropipettes
(Transferpette®, BRAND, Wertheim, Germany) following
the manufacturer instructions for clinical use. Pure-grade
reference powders of both aminoglycosides (Sigma
Aldrich, St Louis, MO) and vancomycin (United States
Pharmacopeia, Rockville, MD) were used as controls. The
former were weighted in an analytical balance (Sartorius,BMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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Goettingen, Germany) and the latter was diluted to a final
concentration of 50 mg/mL in distilled water.
Media, strains and inocula
Testing strains were Bacillus subtilis ATCC 6633 for ami-
kacin (and some experiments with vancomycin), Staphylo-
coccus aureus ATCC 6538p for vancomycin, and
Staphylococcus epidermidis ATCC 12228 for gentamicin.
Seeding agar were Difco™ Antibiotic Media (Becton Dick-
inson & Co, Franklin Lakes, NJ) numbers 5 (amikacin), 8
(vancomycin) and 11 (gentamicin) [24].
To grow S. aureus and S. epidermidis, we followed CLSI
protocols [25]. Briefly, each bacterial stock previously
stored and frozen at -70°C was resuscitated on solid
medium (in two successive Trypticase Soy Agar plates,
Becton Dickinson, Sparks, MD) and five colonies were
selected and passed to 10 mL of Trypticase Soy Broth (five
16 × 125 glass tubes labeled 1 to 5 with successive 1:10
dilutions). After overnight incubation at 37°C, we made a
second transfer from the last tube with visible growth into
10 mL of fresh liquid medium (three 16 × 125 glass tubes
labeled 6 to 8 with successive 1:10 dilutions). This second
set was grown to attain an OD580 nm = 0.300 for S. aureus
and 0.450 for S. epidermidis (Spectro 22®, Labomed Inc.,
Culver City, CA, USA), equivalent to a log-phase culture
with approximately ~108 CFU/mL. We ruled out signifi-
cant impact of S. aureus' cell clusters [26] by multiple
standardizations of growth curves correlating OD with
CFU count (data not shown). For B. subtilis, a spore sus-
pension was prepared by growing the microorganism for
one week at 37°C in a large bottle on Difco™ Antibiotic
Media number 1. Then, the spores were suspended in ster-
ile distilled water and heated for 30 minutes at 65°C,
washed three times, and reheated at 65°C for 30 minutes
before re-suspension in sterile distilled water. The final
suspension containing ~108  CFU/mL was temporarily
maintained at 15°C prior to inoculation of the bioassay
agar.
Device and pouring of glass-plates assay
A 36 × 36 cm glass plate previously described was modi-
fied to allow simultaneous runs in duplicates of all assays
of the different generic products and innovator [27]. The
device was routinely cleaned (iodine soap and water), dis-
infected (70% ethanol) and sterilized (steam autoclaving
at 121°C). The seeding agar (3 mm of depth) was pre-
pared following the manufacturer instructions, dispensed
in a sterile 300 mL flask, and placed into a water bath
(50°C) to maintain the agar in liquid state until poured.
We inoculated the bioassay agar adding 2 mL of log-phase
suspension of S. aureus or S. epidermidis in 100 mL of the
corresponding antibiotic media or adding 3 mL of B. sub-
tilis  spore suspension for each 100 mL of antibiotic
medium. These inoculum sizes (~2 × 106  CFU/mL)
ensured sharply defined zone edges and a good slope
steepness of the log dose-response line.
The solutions were applied in a simple sequential fashion
down the columns, as described by Bennett et al. [27].
Incubation was carried out at 35°C for 18–22 h depend-
ing on the bacteria-agar combination, according with the
instructions of the antibiotic media manufacturer [24].
The same researcher measured the zone sizes in all assays
using an electronic caliper (Mitutoyo Corp., Kawasaki,
Japan).
The use of mouse serum was approved, as well as the com-
plete protocol, by the University of Antioquia Animal
Experimentation Ethics Committee.
Statistical Analyses
We determined the linearity, limit of quantification, pre-
cision, accuracy, and specificity to validate the method for
testing pharmaceutical equivalence. For this purpose, the
log-transformed concentrations (x-axis, log10  mg/L) of
each product were plotted against their respective inhibi-
tion zone sizes (y-axis, mean diameter in mm); intercept
and slope of the best straight line were obtained fitting the
data to a linear model (expressed by the equation y = b +
mx, where b is the y-intercept and m is the slope) by least-
squares regression using SigmaPlot 9.0 (SPSS Inc., Chi-
cago, IL). The concentrations used ranged from 0.5 to 256,
0.125 to 64, and 0.25 to 128 mg/L for amikacin, gen-
tamicin and vancomycin, respectively. The goodness of fit
to the model (linearity) was expressed as coefficient of
determination (r2) and standard error of estimate (Syx).
We also calculated the x-intercept (log10 mg/L) and slope
of the regression line with 95% confidence intervals (95%
CI) [28]. The regression approach to analysis of variance
was used to determine the statistical significance of inter-
cept and slope. Normality and constant variance assump-
tions were checked using Kolmogorov-Smirnov and
Levene's tests, respectively (SPSS 15.0, SPSS Inc., Chicago,
IL). In case of non-equal variance, we applied Welch's test
to confirm the significance of the parameters derived from
the linear model [29].
Using a symmetrical parallel-line assay we tested the phar-
maceutical equivalence comparing slope and intercept of
each generic product with those of the innovator by Over-
all Test for Coincidence of the Regression Lines, a statisti-
cal technique for Curve Fitting Analysis (CFA) (Prism 5.0,
GraphPad Software, Inc., San Diego, CA) [30]. We defined
potency as the slope of the linear regression and concen-
tration as the anti-log of the x-intercept when y = 0. We
also estimated the relative concentration when y is at the
mid-point of the linear regression, because this is the
point of minimal variation using the 95% confidence
interval of the predicted line. Assuming that generic andBMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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Table 1: Source and batch of antibiotics included in the study
Product Code Batch Manufacturer Distributor
AMK-BMS (innovator) 01J115 Bristol-Myers Squibb (BMS), Guayaquil, 
Ecuador
Bristol-Myers Squibb, Cali, Colombia
AMK-Carlon 278V0704 Carlon Ltda, Bogota, Colombia Item
AMK-Gencol 0200 Laboratorios Chalver, Bogota, Colombia Genericos de Colombia (Gencol), Bogota, 
Colombia
AMK-Pisa 121859 Laboratorios Pisa SA de CV, Guadalajara, 
Mexico
Laboratorios ECAR Ltda, Medellin, Colombia
AMK-Scalpi AK010348 Consorcio Farmionni-Lubelca, Bogota, 
Colombia
Farmionni Scalpi SA, Bogota, Colombia
AMK-Sigma (Reference Powder) 120K1643 Sigma Chemical Co, St Louis, MO, USA Not applicable
GNT-SP (innovator) CB3AMKB04 Schering-Plough SA (SP), Bogota, Colombia Item
GNT-Abbott 75-024-DK Abbott Laboratories, North Chicago, IL, USA Not available
GNT-Az pharma 303030 Vitrofarma SA, Bogota DC, Colombia AZ-Pharma SA, Bogota, Colombia
GNT-Biochemie 07102321 Biochemie GmbH, Kundl, Austria Novartis de Colombia SA, Bogota, Colombia
GNT-Biogenta 0402 Laboratorios Chalver, Bogotá, Colombia Chalver Farmaceutica (Biogenta), Bogota 
Colombia
GNT-Colmed 01005 Colmed Internacional, Barranquilla, Colombia Procaps SA, Barranquilla, Colombia
GNT-Genfar 030703 Viteco SA, Bogota, Colombia Lab. Genericos Farmaceuticos, Bogota, 
Colombia
GNT-Lab America 0980303 Arbofarma SA, Bogota, Colombia Laboratorios America SA, Medellin, Colombia
GNT-Labinco 01013C Laboratorios Ryan, Bogota, Colombia Laboratorio Internacional (Labinco), Bogota, 
Colombia
GNT-La Sante 0310 Viteco SA, Bogota, Colombia Laboratorios La Sante, Bogota, Colombia
GNT-Memphis 2208I101 Vitrofarma SA, Bogota, Colombia Memphis products SA, Bogota, Colombia
GNT-MK 3P066 Vitrofarma SA, Bogota, Colombia Tecnoquimica SA (MK), Cali Colombia
GNT-Ophalac 004013 Vitrofarma SA, Bogota, Colombia Laboratorios Farmaceuticos Ophalac, Bogota, 
Colombia
GNT-Pentacoop 33544 Laboratorios Ryan, Bogota, Colombia Pentacoop SA, Bogota DC, Colombia
GNT-Recipe 301094 Vitrofarma SA, Bogota, Colombia Linea Recipe® of Laboratorios Bussié SA, 
Colombia
GNT-Scalpi GE020619 Consorcio Farmionni-Lubelca, Bogota, 
Colombia
Farmionni Scalpi SA, Bogota, Colombia
GNT-Sigma (Reference Powder) 10k1510 Sigma Chemical Co, St Louis, MO, USA Not applicableBMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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innovator are the same product, a pharmaceutically
equivalent generic must display a parallel and overlaid
curve with respect to the innovator (P > 0.05 by CFA). On
the other hand, parallel curves with different intercepts
meant identical APIs but at significantly higher or lower
concentration, while lack of parallelism implied that dif-
ferent products were being tested, without further consid-
erations. We also calculated the relative potency of each
generic to innovator as the x-distance between the two
lines, as recommended by the international pharmaco-
poeias [20].
The limit of quantification was defined visually as the
smallest amount of drug that still produced a clearly dis-
tinguishable inhibition zone around the diameter of an
empty well (3.5 mm). The limit of detection was calcu-
lated using the standard deviation and slope method rec-
ommended by ICH guidelines.
The repeatability of the assay was determined using a min-
imum of three concentrations of each antibiotic by tripli-
cates during the same day or under similar experimental
conditions but with different biological matrices (water
instead of serum to dilute samples) and plates (intra-assay
precision), and comparing the results of assays on differ-
ent days (inter-day precision). These were expressed as
means with standard deviations and coefficients of varia-
tion (CV) [31].
To test the ability of the assay to detect significant differ-
ences in concentration of the API (accuracy), we prepared a
5-point standard curve (two-fold dilutions from 128 to 8
mg/L) using vancomycin reference powder (USP) and com-
pared it with samples containing 10, 15 and 20% more
vancomycin. Briefly, a vial containing 100.5 mg of the anti-
biotic was dissolved in 2.01 mL of distilled water to a final
concentration of 50 mg/mL and serially diluted to achieve
1 mL at 128 mg/L. Then, 0.1 mL aliquots of this solution
were diluted to obtain a set of three extra concentration
groups over three selected points in the standard curve (16,
32 and 64 mg/L): Group I with 10% more (17.6, 35.2 and
70.4 mg/L), Group II with 15% more (18.4, 36.8 and 73.6
mg/L) and Group III with 20% more (19.2, 38.4 and 76.8
mg/L) vancomycin. Intercepts and slopes of linear regres-
sions produced by the reference standard and each extra
group were compared by CFA [32].
Linear regression of the innovator products Figure 1
Linear regression of the innovator products. Linear regression of the concentration-effect relationship of the innovator 
products of amikacin (A), gentamicin (B) and vancomycin (C) showing minimal scatter and excellent fit (r2 ≥ 0.993) of the data 
to the model.
VAN-Lilly (Innovator) A014744 Eli Lilly & Compañia de Mexico, Mexico Eli Lilly Interamericana Inc., Bogota, Colombia
VAN-Abbott 03703Z7 Abbott Laboratories, Chicago, IL, USA Abbott Laboratories de Colombia, Bogota, 
Colombia
VAN-APP 120740 American Pharmaceutical Partners (APP), LA, 
USA
Comedica Ltda., Bogota, Colombia
VAN-Proclin 6679 Laboratorios Northia S.A.C.I.F.I.A, Argentina Proclin Pharma SA, Bogota, Colombia
VAN-USP 70900L United States Pharmacopeia (USP), Rockville, 
MD, USA
Not applicable
Table 1: Source and batch of antibiotics included in the study (Continued)BMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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Table 2: Potency estimate and parameters derived from linear regression with their statistical comparison of generics versus 
innovator by Curve Fitting Analysis
Product r2 Intercept [95% CI] P-value Slope [95% CI] P-value Potency Estimate (%)
AMK-BMS 0.99 9.006 [8.646 to 9.366] 0.8799 3.884 [3.619 to 4.148] 0.6559 100.00
AMK-Carlon 0.99 9.082 [8.651 to 9.514] 3.789 [3.472 to 4.105] 99.83
AMK-Gencol 0.99 9.238 [8.738 to 9.737] 3.731 [3.365 to 4.098] 100.51
AMK-Pisa 0.99 9.244 [8.860 to 9.629] 3.698 [3.416 to 3.980] 100.31
AMK-Scalpi 0.99 8.920 [8.552 to 9.287] 3.935 [3.665 to 4.204] 99.77
AMK-Sigma 0.99 8.945 [8.575 to 9.315] 3.926 [3.655 to 4.198] 99.89
GNT-SP 0.99 10.44 [10.16 to 10.720] 0.9472 3.881 [3.594 to 4.167] 0.9984 100.00
GNT-Abbott 0.98 10.00 [9.557 to 10.440] 4.150 [3.695 to 4.605] 99.72
GNT-Az pharma 0.98 10.02 [9.576 to 10.460] 4.021 [3.570 to 4.473] 99.68
GNT-Biochemie 0.98 10.08 [9.668 to 10.500] 4.038 [3.613 to 4.463] 99.75
GNT-Biogenta 0.98 10.13 [9.736 to 10.510] 3.925 [3.526 to 4.324] 99.74
GNT-Colmed 0.98 10.13 [9.701 to 10.550] 3.918 [3.483 to 4.354] 99.74
GNT-Genfar 0.99 10.04 [9.697 to 10.380] 4.091 [3.738 to 4.443] 99.73
GNT-Lab America 0.99 10.09 [9.708 to 10.470] 4.143 [3.754 to 4.532] 99.79
GNT-Labinco 0.99 10.11 [9.749 to 10.470] 3.994 [3.623 to 4.366] 99.76
GNT-La Sante 0.98 10.11 [9.668 to 10.550] 4.106 [3.655 to 4.558] 99.80
GNT-Memphis 0.98 10.15 [9.694 to 10.610] 3.935 [3.465 to 4.406] 99.77
GNT-MK 0.98 10.09 [9.672 to 10.510] 4.146 [3.715 to 4.577] 99.68
GNT-Ophalac 0.98 10.02 [9.571 to 10.460] 4.006 [3.549 to 4.463] 99.68
GNT-Pentacoop 0.98 10.13 [9.690 to 10.560] 3.962 [3.514 to 4.409] 99.76
GNT-Recipe 0.98 10.10 [9.700 to 10.510] 3.926 [3.512 to 4.340] 99.72
GNT-Scalpi 0.98 10.13 [9.720 to 10.540] 3.919 [3.501 to 4.337] 99.74
GNT-Sigma 0.98 10.36 [9.889 to 10.830] 4.109 [3.629 to 4.590] 100.02
VAN-Lilly 0.99 6.320 [5.715 to 6.924] 0.0201 5.562 [5.082 to 6.042] 0.8594 100.00
VAN-Abbott 0.99 5.782 [5.248 to 6.316] 5.558 [5.134 to 5.982] 98.51
VAN-APP 0.99 6.281 [5.734 to 6.828] 5.359 [4.925 to 5.793] 99.30
VAN-Proclin 0.99 6.388 [5.721 to 7.054] 5.462 [4.933 to 5.991] 99.90BMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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To show the ability of the microbiological assay to unam-
biguously assess the API in presence of all other expected
components in a pharmaceutical-grade product for clini-
cal use (specificity), it was necessary to subject the innova-
tor of vancomycin to specific stress conditions to increase
degradation subproducts. In this case, we compared by
CFA the intercept and slope of a freshly prepared standard
curve (16 to 256 mg/L) against those obtained after 2, 4,
8 and 16 hours of heating at 80°C.
Results
Antibiotics
Table 1 shows detailed information for all amikacin
(AMK), gentamicin (GNT) and vancomycin (VAN) prod-
ucts studied. All reference powders (100%), 1 of 4 (25%),
2 of 15 (13%), and 3 of 3 (100%) generics of AMK, GNT
and VAN, respectively, were manufactured outside
Colombia and legally imported for clinical use. It should
be noted that one company (Vitrofarma SA, Bogota,
Colombia) manufactured 5 of 15 (33%) generics of GNT.
Goodness of fit of the linear regression model to data
Figure 1 shows the log concentration-response relation-
ship and the best straight line predicted from data
obtained by microbiological assay for the innovator of
amikacin (A), gentamicin (B) and vancomycin (C). All
cases exhibited a linear relationship between the loga-
rithm of the concentration (log10 mg/L) and the diameter
(mm) of the zones of inhibition with high coefficients of
determination (r2 ≥ 0.991), low standard errors of the esti-
mate (Syx ≤ 0.358) and statistically significant intercept
and slope (P < 0.001 by ANOVA). Almost all products
passed normality and constant variance tests, except for
some amikacin generics that failed the Levene's test.
Multiple linear regression for all generics and their respective innovators Figure 2
Multiple linear regression for all generics and their respective innovators. Except for VAN-Abbott (black circles on 
panel C), data of concentration-effect relationship of all generic products are overlaid and can be described by the simple 
regression (black line) of the innovator product of amikacin (A), gentamicin (B) and vancomycin (C). Significant difference in the 
intercept of VAN-Abbott is evident by its linear regression behavior (black short dash line on panel C) compared with the 
regression of the innovator.
Pharmaceutical equivalence determined by comparison of the relative potency of the generic products against the innovator Figure 3
Pharmaceutical equivalence determined by comparison of the relative potency of the generic products against 
the innovator. Relative potency at the linear regression midpoint (mean and 95% CI) of the innovator and generic products 
of amikacin (2A), gentamicin (2B) and vancomycin (2C). Except for vancomycin Abbott, there were no significant differences in 
potency between generics and their corresponding innovator, confirming pharmaceutical equivalence.BMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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Welch-ANOVA confirmed the significance of parameters
derived from the linear regression for these products (P <
0.0001).
Determination of pharmaceutical equivalence
Except for one generic product (VAN-Abbott) that exhib-
ited a different intercept (P < 0.008 by CFA), the log con-
centration-response relationships of all generic products
and reference powders were parallel and overlaid to their
respective innovator linear curve without significant dif-
ference by CFA (P ≥ 0.656, Table 2), demonstrating that
all products had the same biologic activity (potency) and
concentration (intercept). The high goodness of fit of the
model allowed the use of innovator product equations as
common linear equations for all generics (Figure 2, panels
A to C) to predict the concentration (mg/L) of a sample
(generic product) from an inhibition zone (mm).
The potency estimate of generic products ranged from
99.77 to 100.5, 99.68 to 100.2 and 98.51 to 99.9% relative
to the innovator of amikacin, gentamicin and vancomycin,
respectively (Table 2). In the same order, the comparison of
relative concentrations of all generic products at the mid-
point of their linear regression against the innovator by
confidence intervals did not show significant differences
(Figure 3, panels A to C), except for VAN-Abbott that dis-
played the same potency and 25% greater concentration of
API (16.2 ± 1.05 vs. 12.9 ± 1.06 mg/L, P = 0.001).
Other validation parameters
The calculated limits of quantification were 0.13, 0.10
and 0.15 mg/L for amikacin, gentamicin and vancomy-
cin, respectively. Table 3 shows the results of repeatabil-
ity in a five-concentration assay (8 to 128 mg/L) for the
Table 3: Precision of the vancomycin bioassay
Vancomycin concentration 
(mg/L)
Inhibition zone diameters 
(mean in mm ± SD)
Coefficient of variation (%) 
Intra-day
Coefficient of variation (%) 
Inter-day
128 18.00 ± 0.04 8.3 10.3
64 16.33 ± 0.02 5.6 10.5
32 14.16 ± 0.11 11.0 1.0
16 11.62 ± 0.37 7.4* 2.3
8 9.59 ± 0.00 4.6 6.5
*An outlier value was excluded from the calculations (we only used five data to compute the CV)
Linear regression of the concentration-effect relationship of  vancomycin diluted in different media (water and murine  serum) Figure 4
Linear regression of the concentration-effect rela-
tionship of vancomycin diluted in different media 
(water and murine serum). There was no statistically sig-
nificant difference between the two data sets, showing that 
all points fit better to a single line, and the assay is not 
affected by changes in the biological matrix.
Comparison of a standard curve of innovator vancomycin  with samples containing 10% (red), 15% (blue) and 20%  (green) more antibiotic Figure 5
Comparison of a standard curve of innovator vanco-
mycin with samples containing 10% (red), 15% (blue) 
and 20% (green) more antibiotic. The curve fitting analy-
sis showed no difference in slopes (i.e. all samples had the 
same biological activity) but significantly different intercept 
(i.e. more concentration) in the 20% group (indicating the 
threshold for statistical significance of the assay).BMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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reference powder of vancomycin performed the same
day using different plates (intra-assay variation), and
working on different days (inter-day variation). The CV
ranged from 4.6% to 11.0% within the same day, and
from 1.0% to 10.3% between days, respectively. Wil-
coxon signed-rank test did not show significant differ-
ences between the results of similar experiments made in
different days (P = 0.426). The variation of the bioassay
was also assessed using different biological matrices
(mouse serum vs. distilled water) as diluents (Figure 4).
There were no statistical differences comparing the linear
regression of each matrix by CFA (Py-intercept = 0.311 and
Pslope = 0.857).
Figure 5 shows the accuracy of the assay to detect changes
in concentration of the same API. Whereas the CFA com-
parison of the slopes produced by the standard and extra-
vancomycin concentration groups did not show differ-
ences (P = 0.219), we found a significant difference (as
expected) in the y-intercepts (P = 0.0002). These results
corroborate that our method can discriminate changes of
concentration (intercept) even for API with identical bio-
logic activity (slopes). To define the group responsible for
the observed y-intercept difference, we used an Overall
Test for Coincidence of Two Linear Regressions (each
group versus standard), which only showed a significant
difference between the standard vancomycin curve and
the 20% extra-concentration group (P = 0.045).
Figure 6 shows the impact on the linear regression of heat-
ing vancomycin (16 to 256 mg/L) at 80°C for 2, 4, 8 and
16 hours compared against that produced by a standard
curve of fresh vancomycin (at room temperature). Inde-
pendently of heating time, significant changes on API con-
centration (Py-intercept < 0.0001) could be detected by the
method without evidence of modification on the biological
activity (Pslope = 0.2985). Compared with fresh vancomycin,
the inhibition zones diminished proportionally to the
heating time and the curves were below the control at room
temperature. The percentage of recovery of active ingredient
of vancomycin ranged from 69 to 83, 44 to 64, 39 to 54 and
31 to 44% after 2, 4, 8 and 16 hours, respectively.
Discussion
The microbiological assay has been used extensively to
estimate the potency of growth-inhibiting substances by
comparing their quantitative effect with a reference stand-
ard of defined potency [14,33,34]. Here, we developed a
different application aimed to compare with a gold stand-
ard (innovator) the concentration and potency of phar-
maceutical-grade generic products for intravenous use. To
our knowledge, it is the first time that the bioassay is val-
idated to determine pharmaceutical equivalence of
generic intravenous antibiotics.
It is a common belief that, being a biological assay, the
agar-diffusion assay is subject to biological error and
therefore less reliable than physicochemical methods (e.g.
HPLC) [13]. However, different to the macrobiological
assay that uses a limited number of higher organisms
(usually animals) with a natural variability, the microbio-
logical assay employs tens of millions of individuals (bac-
teria) as biological indicators that usually react uniformly
to the active substance tested. Therefore, the biological
error is not the usual source of error in microbiological
assays, allowing meaningful results with a precision simi-
lar to any chemical or physicochemical method
[16,33,35]. In fact, we observed an excellent goodness of
fit of the linear regression model to data (r2 ≥ 0.99; Syx ≤
0.358) with highly precise results and minimal intraday
and inter-day variation (Table 3), which is very close to
physicochemical methods (~8%), and with good accuracy
and sensitivity permitting to detect significant differences
on API concentration either by excess (Figure 5) or defect
(Figure 6). Furthermore, our method widely exceeds the
linearity, precision and accuracy requirements for valida-
tion of the international pharmacopoeias (i.e. FDA) for
physicochemical methods [20,36]. Considering that phar-
maceutical equivalence implies to prove that the API con-
centration in a generic product is located within an
accepted range respect to a gold standard (80–120%), pre-
cision and accuracy of the method are the most important
criteria to be considered. Bearing in mind that we com-
pared active ingredients and not pharmaceutical impuri-
Effect of heating at 80°C on vancomycin samples over a 16- hour period Figure 6
Effect of heating at 80°C on vancomycin samples 
over a 16-hour period. Compared with the fresh product, 
the concentration of active principle gradually declines (as 
shown by different intercepts). The identical slopes indicate 
that the assay only measures the vancomycin active principle 
and that degradation products lack significant biological activ-
ity.BMC Clinical Pharmacology 2009, 9:1 http://www.biomedcentral.com/1472-6904/9/1
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ties, our results suggest that the bioassay is as good as
physicochemical methods to correctly determine pharma-
ceutical equivalence of biologic products (antibiotics)
[37].
The mathematical principles employed to compare
generic and innovators are simple and derived from the
well-known guidelines for parallel-line assays established
by regulatory agencies [13,14,38,39]. Here, we employed
curve fitting analysis to compare the linear regressions of
generics against the innovator and defined concentration
and potency using the same parameters (y-intercept and
slope, respectively) of the linear equation. Logically, if a
generic drug is identical to the innovator, then their stand-
ard curves (intercept and slope) from a bioassay should
not differ significantly (pharmaceutical equivalents).
As we confirmed for vancomycin, adding or subtracting
active principle to the same product induces a correspond-
ing shift in the intercept of the concentration-response
curve without affecting the slope (potency). The assay is
sensitive to detect variations in concentration ≥ 120% (see
20% extra-concentration group in Figure 5) and ≤ 85%
(see 2 hours post-incubation group in Figure 6). These val-
ues are similar to the variation range (80 to 120%) of API
concentration accepted for many generic antibiotics [20].
As we expected, almost all generics approved by the drug
regulatory agency in Colombia (except by VAN-Abbott)
were identical to the innovator displaying equal slopes
(potency) and intercepts (concentration) as demonstra-
tion of their pharmaceutical equivalence. It has not
escaped our attention that the concentration and slope of
all five gentamicin products produced by the same manu-
facturer were pharmaceutical equivalents and did not
exhibit contradictory results (Table 2).
Vancomycin for clinical use is a mixture of active principle
(factor B) and impurities (crystalline degradation prod-
ucts or CDP-1) that differ widely in inhibitory potency
(factor B at least 1000-times superior to CDP-1) [40,41].
The exposure of innovator vancomycin to heat, previously
described by Sheldrick et al [42,43], progressively induces
the conversion of factor B to CDP-1, reducing the concen-
tration of the active principle (intercept) without affecting
the original potency (slope) of the product (Figure 6).
However, the concentration of these degradation products
cannot be measured, certainly a limitation for evaluating
impure drugs (i.e. oral forms) or prodrugs (e.g. clindamy-
cin phosphate) by our method.
As stated earlier, therapeutic equivalence of generic intra-
venous antibiotics is based solely on the demonstration of
their pharmaceutical equivalence without further testing.
Considering the critical importance of antiinfective chem-
otherapy in terms of disease control and emergence of
resistance, it is necessary to test the assumption that phar-
maceutical equivalent generics are also therapeutic equiv-
alent to innovators. The methodology described here
constitutes the first step in this direction prior to validate
an animal model of infection or a clinical trial to test in
vivo efficacy and correlate it with the microbiological
assay results.
Conclusion
The microbiological assay demonstrated to be a precise,
reliable and suitable method to determine pharmaceuti-
cal equivalence of intravenous antibiotics by comparison
of their concentration and potency.
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